Malignant Peripheral Nerve Sheath Tumour in a Patient of Type 1 Neurofibromatosis

AMITAVA SENGUPTA,1 ANKAN BANDYOPADHYAY,2 DEBRAJ JASH,3 KAUSHIK SAHA4

Abstract:
Malignant peripheral nerve sheath tumours (MPNST) constitute a rare type of soft tissue sarcoma which arises from peripheral nerves or Schwann cells, perineural cells or fibroblasts. MPNST is a rare neoplasm affecting 1 in 1,00,000 population. Here we report a case of a 36 year old male who presented to us with an upper abdominal swelling for last 3 months. At first, a diagnosis of type 1 neurofibromatosis type I (NF-1) was made. Contrast enhanced CT scan abdomen and thorax revealed presence of a complex, heterogeneous mass in upper abdomen with extension towards left hemithorax. Histopathological examination done from true cut biopsy specimen of the mass was suggestive of malignant peripheral nerve sheath tumour. Positivity of tumour cells on immunohistochemistry to S-100 established the diagnosis of MPNST in type I neurofibromatosis. In conclusion, it was a rare case of MPNST in a patient of NF-1.

Keyword: Malignant peripheral nerve sheath tumour, Neurofibromatosis type I, Upper abdominal mass

Introduction:
Malignant peripheral nerve sheath tumours (MPNST) are sarcoma which arises from peripheral nerves or from cells associated with nerve sheath. In general, sarcoma arising from peripheral nerve or neurofibroma is considered to be a MPNST. The incidence of malignant peripheral nerve sheath tumour (MPNST) in general population is 0.001%. Its incidence in patients with Neurofibromatosis type 1 (NF-1) is 4.6%. Here we present a rare case of MPNST which extended to thorax after originating inside the abdomen in a patient of NF-1.

Case report:
A 36 year old male presented with pain and upper abdominal swelling for last 3 months along with heaviness of chest for last 2 months. On general survey, there was presence of multiple cafe au lait macules 2cm in diameter all over the trunk. Patient also had numerous neurofibroforma all over the body with axillary and inguinal freckles. So, a diagnosis of type 1 neurofibromatosis (NF-1) was made. Examination findings of respiratory tract were suggestive of left sided pleural effusion. On abdominal examination a tender, firm to hard (10cm x 8cm) epigastric swelling was noted with fixity to underlying structure and overlying skin. Cardiovascular and neurological examination were within normal limit. Contrast enhanced CT scan of abdomen and thorax showed a large (11cm x 17cm) complex heterogeneous upper abdominal mass with upward extension towards left hemithorax along the paracardiac region in the left lung up to the horizontal level of main pulmonary artery (Figure 1).

Fig.-1: Contrast enhanced CT scan of abdomen showing a large (11cm x 17cm) complex heterogeneous upper abdominal mass.
There was also presence of massive left sided pleural effusion with lung mass. (Figure 2).

CT guided fine needle aspiration cytology (FNAC) from the abdominal mass showed fat globules, necrosed materials and pleomorphic spindle cells. Histopathological examination from the trucut biopsy specimen from the mass showed interlacing fascicles of spindle shaped to oval cells with vesicular nuclei. Tumour cells demonstrated moderate nuclear pleomorphism and exhibit brisk mitotic activity (mitotic count>6/10HPF) (Figure 3).

**Fig.-2: CT scan thorax with contrast showing left lung mass with pleural effusion.**

**Fig.-3: Biopsy specimen showing interlacing fascicles of spindle shaped to oval cells with vesicular nuclei and demonstrating moderate nuclear pleomorphism with brisk mitotic activity.**

Plenty of blood vessels with thrombus within it and areas of necrosis was seen. On immunohistochemistry, the tumour cell was S100 positive, immunonegative to c-kit and CD34. Mib levelling index was 70%. In context of history of NF-1, the above histopathological picture was suggestive of MPNST. CT scan and MRI of brain did not reveal any abnormality. On thoracotomy, the mass was fixed to the diaphragm and parietal wall with extension to the abdomen. So, resection of the tumour could not be done. Patient received chemotheraphy with doxorubicin, cyclophosphamide and vincristin for 2 cycles after which he died subsequently.

**Discussion:**

NF-1 is an autosomal dominant genetic disorder with a prevalence of approximately 1 in 4,000 births and no racial predilection.\(^1\) NF-1 is diagnosed by any two of the six criteria (1) Multiple cafe-au-lait macules larger than 1.5cm in diameter and more than six in number. (2) Axillary or inguinal freckles, Two or more neurofibromas of any type or one plexiform neurofibroma, (3) Sphenoid wing dysplasia or congenital bowing of long bone cortex with or without pseudoarthrosis, (4) Bilateral optic nerve glioma, two or more Lisch nodules on slit lamp examination, (5) First degree relative with NF1 diagnosed by preceding criteria.

A sarcoma is defined as MPNST if at least two of the following criteria are met with. (1) It arises from a peripheral nerve, (2) It arises from a pre-existing benign nerve sheath tumour (neurofibroma), (3) It demonstrates Schwann cell differentiation on histological examination. The incidence of MPNST in general population is 0.001%. Its incidence in patients with NF1 is 4.6%.\(^2\) Up to 50% of MPNST occurring in patients with NF1 arises from a pre-existing neurofibroma.\(^3\) Overall NF1 patients have a 4% lifetime risk of ultimately developing a MPNST.\(^4\) MPNST in patients of NF-1 generally occurs in adulthood, median age being 30 years only.\(^5\) MPNSTs most commonly occur in the deep soft tissues, usually close to a nerve trunk. The most common sites are the sciatic nerve, brachial plexus, and sacral plexus. It usually presents as an enlarging palpable mass. Pain is a variable complaint. Rapid enlargement occurs more often in patients of NF1. Neurofibromas typically have low attenuation on CT, which may be related to the fat content of myelin from Schwann cells, the high water content of myxoid tissue, entrapment of fat, and cystic areas of hemorrhage and necrosis.\(^6\) MPNST arising from a peripheral nerve may result in variable clinical patterns including radicular pain, paresthesia and motor weakness of muscles. Haematogenous metastasis from MPNST occurs most commonly in lungs.\(^7\) S-100 is traditionally regarded as the best marker for malignant peripheral nerve sheath tumour; however, it is positive in only about one third to half the tumors.\(^8\) The negative reaction may be caused by not only tumour cell anaplasia but also by different constituents other than Schwann cell. All perineural MPNST were S100 protein negative and EMA and/or GLUT1 positive. For the immunohistochemical diagnosis of MPNST, nerve sheath markers other than S100 protein such as CD57 (Leu7), EMA, Glut1, CD34 should also be included in the panel of antibodies.\(^9\)
The reported five year survival for patients with MPNST without NF1 is as high as 50%. It drops down to as low as 10% in MPNST patients with NF1.\(^7\)

Treatment consists of complete and wide surgical resection.\(^10\) Adjuvant irradiation seems to improve local control of the disease. Use of chemotherapy is only employed in high grade disease in which metastatic disease is likely. Chemotherapy can be administered in preoperative or postoperative settings. The prognosis depends on tumour size, surgical excision margin, and histological presence of necrosis and history of prior irradiation.\(^8\) MPNST itself is a rare disease. Moreover MPNST being associated with NF-1 was more uncommon. Initial Presentation having abdominal mass with extension into the lung made the case more atypical. Patient did not respond to chemotherapy as he fell into bad prognosis group due to presence of large size tumour, failure of surgical resection and presence of necrosis in the histopathological specimen.

**Conflict of Interest : None**

**References:**

8. Johnson MD, Glick AD, Davis BW. Immunohistochemical evaluation of Leu-7, myelin basic protein, S-100 protein, glial fibrillary acidic protein, and LN3 immunoreactivity in nerve sheath tumors and sarcomas. Arch Pathol Lab Med 1988; 112:155-60